^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

entrectinib (Rozlytrek®) is accepted for use within NHSScotland.

Published date:
12/04/2020
Excerpt:
entrectinib (Rozlytrek®) is accepted for use within NHSScotland...Indication under review: as monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
Evidence Level:
Sensitive: A1 - Approval
Published date:
07/31/2020
Excerpt:
Rozlytrek can also be used for treating adults with advanced non-small-cell lung cancer that has a genetic abnormality called ROS1 gene fusion. It should be used only if the patient has not been treated previously with a medicine that blocks ROS1.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 13 substudy 31: Entrectinibn

Excerpt:
...Harbouring an NTRK fusion or ROS1 activating gene alteration identified using CGP...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Excerpt:
...Confirmed diagnosis of a ROS1 gene fusion-positive malignancy, other than NSCLC, that has been identified using an analytically validated sequencing technique....
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

264P - Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp non-small cell lung cancer (NSCLC)

Published date:
11/28/2022
Excerpt:
This updated analysis with longer follow-up provides further evidence that entrectinib is associated with deep and durable responses in Chinese pts with NTRK-fp solid tumours or ROS1-fp NSCLC.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

390P - Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours

Published date:
11/28/2022
Excerpt:
In total, 20 pts with ROS1-fp NSCLC and 10 pts with NTRK-fp solid tumours (5 salivary, 1 breast, 1 colorectal, 1 NSCLC, 1 sarcoma, 1 thyroid) were efficacy evaluable. For both cohorts, median survival follow-up was 38.6 mos and ORR was 70%....The 24-mos OS rates were 65% (ROS1-fp NSCLC) and 90% (NTRK-fp solid tumours). In pts without baseline CNS mets by investigator, ORR was 76% (ROS1-fp NSCLC; n=13/17) and 75% (NTRK-fp solid tumours; n=6/8). In pts with baseline CNS mets by BICR (3 ROS1-fp; 1 NTRK-fp), one pt (NTRK-fp) had an IC response....Entrectinib showed deep and durable responses and manageable safety in Japanese pts with locally advanced/metastatic ROS1-fp NSCLC or NTRK-fp solid tumours
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

WS08.11 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

Published date:
07/12/2022
Excerpt:
In patients with BICR-assessed baseline CNS metastases (n=51), median IC-ORR was 49% (25/51; 95% CI 34.8-63.4); median IC-DoR was 12.9 months (95% CI 7.6-22.5); median IC-PFS was 12.0 months (95% CI 6.7-15.6). In patients who received entrectinib as first-line treatment (n=67; exploratory analyses; Table), ORR was 69% (95% CI 56.2-79.4), median DoR was 35.6 months (95% CI 13.9-38.8); median PFS was 17.7 months (95% CI 11.8-39.4). In this updated analysis with longer follow-up and a larger patient population, entrectinib continues to demonstrate overall and intracranial efficacy, and a manageable safety profile in patients with ROS1-fp NSCLC.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion positive (fp) NSCLC and NTRK-fp solid tumours

Published date:
03/23/2022
Excerpt:
Adult Chinese pts with ROS1- and TRK- TKI-naïve, ROS1-fp locally advanced/metastatic NSCLC or NTRK-fp solid tumours were enrolled....In Chinese pts with locally advanced/metastatic ROS1-fp NSCLC or NTRK fp solid tumours, with or without baseline CNS metastases, entrectinib induced deep and durable responses.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

Published date:
04/27/2021
Excerpt:
SA-PRO populations comprised patients with NTRK fusion-positive solid tumours (N = 88) or ROS1 fusion-positive non-small-cell lung cancer (N = 180) who received one or more doses of entrectinib...Both cohorts reported low-to-moderate symptom burden at baseline, which was maintained or trended towards clinically meaningful improvement.
DOI:
10.1016/j.esmoop.2021.100113
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements

Published date:
03/15/2021
Excerpt:
In patients with ROS1-positive NSCLC, the ORR was 67.1% (95% CI 59.25% to 74.27%) and the median DOR was 15.7 months (95% CI 13.9-28.6 months)....ROS1-rearranged NSCLC indication, entrectinib showed antitumour activity by inducing a relevant ORR of some durability, confirmed with longer follow-up and a larger dataset.
DOI:
10.1016/j.esmoop.2021.100087
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Published date:
03/01/2021
Excerpt:
We report the results of an updated integrated analysis of three phase I or II clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2) of the ROS1 tyrosine kinase inhibitor, entrectinib, in ROS1 fusion-positive NSCLC….The ORR was 67.1% (n = 108, 95% CI, 59.3 to 74.3)...The 12-month PFS rate was 55% (median PFS 15.7 months), and the 12-month OS rate was 81%...Entrectinib continued to demonstrate a high level of clinical benefit for patients with ROS1 fusion-positive NSCLC, including patients with CNS metastases.
DOI:
10.1200/JCO.20.03025
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1287P - Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis

Published date:
09/14/2020
Excerpt:
This updated analysis, using a larger dataset with longer follow-up, shows that entrectinib induces clinically meaningful responses in pts with ROS1-fp NSCLC, including pts with CNS metastases at baseline…
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1288P - Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline

Published date:
09/14/2020
Excerpt:
Entrectinib induced clinically meaningful intracranial responses in pts with NTRK-fp or ROS1-fp NSCLC with CNS metastases at baseline. Intracranial ORR, median intracranial DoR and median intracranial PFS for these two cohorts are shown in the table.
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Excerpt:
In the 25 patients with measurable baseline CNS metastases, the intracranial ORR was 80% (95% CI: 59.3–93.2), median intracranial DoR was 12.9 months, and median intracranial PFS was 8.8 months. Among 18 patients with CNS-only progression on previous crizotinib treatment, two achieved a partial response (11%) and four had stable disease (22%). In seven patients with measurable CNS disease from this cohort, the intracranial ORR was 14% (1 partial response)....Entrectinib is active and achieves prolonged survival in ROS1 TKI–naïve patients with ROS1 fusion–positive NSCLC.
DOI:
https://doi.org/10.1016/j.jtocrr.2022.100332